Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec SE reports developments in drug discovery and development services, integrated R&D programs and strategic partnerships with pharmaceutical, biotechnology, academic and health-focused organizations. Its updates commonly cover small-molecule, biologics and cell-therapy work; AI/ML-enabled platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling; and therapeutic programs in oncology, cardiovascular and metabolic disease, neurology, immunology and infectious disease.
Recurring news also includes Just - Evotec Biologics manufacturing and biologics-development activity, grant-funded global-health work, preclinical candidate nominations, financial results and business updates. Governance items include Supervisory Board nominations, management appointments and operating-model changes tied to the company’s global R&D and partnership infrastructure.
Evotec SE (NASDAQ:EVO) has signed a non-binding agreement with Sandoz AG for the potential sale of its Just - Evotec Biologics EU facility in Toulouse, France. The proposed transaction is valued at approximately $300 million in cash, with additional technology-related considerations including future development revenues, milestones, and product royalties.
Under the agreement, Sandoz would acquire full ownership of the Toulouse site, while Evotec maintains potential economic benefits through various revenue streams. The transaction is expected to enhance Evotec's revenue mix, profit margins, and capital efficiency. The deal's completion is subject to employee consultation processes, final agreements, and regulatory approvals.
Evotec SE (NASDAQ:EVO) has signed a non-binding agreement with Sandoz AG for the potential sale of Just - Evotec Biologics EU's Toulouse facility for approximately US$ 300 million in cash, plus additional technology-related considerations, future development revenues, milestones, and product royalties.
The transaction involves transferring the J.POD biologics manufacturing facility in Toulouse, France, which has been dedicated to Sandoz since July 2024, along with granting access to Evotec's proprietary platform for integrated development and advanced continuous manufacturing of biologics. The deal is expected to close in Q4 2025, subject to regulatory requirements and employee consultation processes.
This strategic move aligns with Evotec's new direction toward an asset-lighter and capital-efficient business model, aimed at leveraging its technology & IP while scaling service offerings. The transaction is expected to immediately enhance Evotec's revenue mix, profit margins, and capital efficiency.
Evotec SE (NASDAQ:EVO) has revised its fiscal year 2025 revenue guidance downward to €760-800 million from the previous €840-880 million, while maintaining its R&D and adjusted EBITDA guidance. The company's new strategy for sustainable growth is showing early results, with stronger-than-expected contributions from high-margin technology license deals.
Despite challenging market conditions affecting its Shared R&D base business in H1 2025, Evotec's cost optimization efforts through its Priority Reset program are exceeding initial targets. The company maintains its Outlook 2028, targeting revenue CAGR of 8-12% (2024-2028) and an adjusted EBITDA margin above 20% by 2028.
The strategic pivot towards a capex-lighter model and focus on high-margin technology licensing is expected to positively impact the company's margin profile.
Evotec SE (NASDAQ:EVO) has revised its revenue guidance for fiscal year 2025 while maintaining its profit outlook. The company now expects group revenues of €760-800 million, down from the previous guidance of €840-880 million. Despite lower revenue projections, Evotec maintains its adjusted EBITDA guidance of €30-50 million and R&D expenditure forecast of €40-50 million.
The guidance adjustment reflects a shift in revenue mix and successful cost-saving initiatives from the Priority Reset program. While technology licensing is showing stronger performance, the Shared R&D base business faces challenging market conditions. First-half 2025 revenues were below expectations, though adjusted EBITDA remained aligned with projections.
Evotec SE (NASDAQ:EVO) has joined the NURTuRE-AKI consortium to study acute kidney injury (AKI) through a comprehensive patient cohort study. The initiative will collect longitudinal data and biological samples from three key patient groups: iatrogenic AKI following cardiac surgery, AKI to chronic kidney disease transition, and pediatric AKI.
The study will integrate with Evotec's Molecular Patient Database (E.MPD), conducting state-of-the-art omics analyses on blood, urine, and research biopsy samples. This collaboration aims to identify novel therapeutic targets and biomarkers for AKI treatment, addressing a significant unmet medical need.
Evotec SE (NASDAQ: EVO) has secured a $2.5 million grant from The Gates Foundation to advance the development of next-generation tuberculosis (TB) treatment regimens. This marks the second grant from the foundation focused on evaluating improved TB therapies using Evotec's translational platforms.
The new funding extends a successful five-year partnership that has already produced standardized preclinical data for selecting shorter, safer, and more effective TB drug combinations. Evotec will utilize its integrated TB platform to further characterize promising treatment regimens, aiming to accelerate the development of transformative TB treatments.
Evotec SE has scheduled the announcement of its first quarter 2025 financial results for Tuesday, May 6, 2025. The company will host a conference call and webcast to discuss the quarterly performance and provide business updates.
The event details include:
- Date: Tuesday, May 6, 2025
- Time: 2:00 PM CEST (1:00 PM BST, 8:00 AM EDT)
- Format: Audio webcast with presentation slides
- Language: English
Participants can join via web or phone, with pre-registration required for dial-in access. The presentation will be available simultaneously for phone participants, and an on-demand version will be accessible through Evotec's website under Financial Publications.
Evotec SE (NASDAQ:EVO) has announced significant progress in its strategic research collaboration with Bristol Myers Squibb, triggering total payments of US$ 75 million to Evotec through performance-based and program-based achievements.
The collaboration, initiated in 2018 and expanded in 2022, combines Evotec's high-performance multi-omics screening and AI-supported data analytics with Bristol Myers Squibb's cereblon E3 ligase modulators (CELMoDs™) library. The partnership focuses on developing molecular glue degraders for high-value targets in oncology and other therapeutic areas.
The collaboration continues to advance its pipeline of molecular degraders, aiming to deliver multiple first-in-class products to market for unmet medical needs.
Evotec SE (NASDAQ:EVO) has announced its FY 2024 results and unveiled a new strategic direction focused on drug discovery and biologics. The company reported a 2% revenue increase to €797.0 million, with Q4 2024 revenues up 10% to €221.2 million.
Key highlights include:
- Just - Evotec Biologics segment grew 71% year-over-year to €185.6 million
- Adjusted Group EBITDA reached €22.6 million
- Priority Reset program on track to deliver €40 million in annual savings
- Net debt leverage ratio improved to 1.9x
For 2025 guidance, Evotec expects:
- Revenue range of €840-880 million
- R&D expenditure of €40-50 million
- Adjusted Group EBITDA of €30-50 million
The company's 2028 outlook targets revenue CAGR of 8-12% (2024-2028) and adjusted EBITDA margin above 20%.